

In Vivo and *In Vitro* Protein Ligation by Naturally Occurring and Engineered Split DnaE Inteins

A. Sesilja Aranko, Sara Züger^{1a}, Edith Buchinger^{1b}, Hideo Iwai*

Research Program in Structural Biology and Biophysics, Institute of Biotechnology, University of Helsinki, Helsinki, Finland

Abstract

Background: Protein *trans*-splicing by naturally occurring split DnaE inteins is used for protein ligation of foreign peptide fragments. In order to widen biotechnological applications of protein *trans*-splicing, it is highly desirable to have split inteins with shorter C-terminal fragments, which can be chemically synthesized.

Principal Findings: We report the identification of new functional split sites in DnaE inteins from *Synechocystis sp.* PCC6803 and from *Nostoc punctiforme*. One of the newly engineered split intein bearing C-terminal 15 residues showed more robust protein *trans*-splicing activity than naturally occurring split DnaE inteins in a foreign context. During the course of our experiments, we found that protein ligation by protein *trans*-splicing depended not only on the splicing junction sequences, but also on the foreign extein sequences. Furthermore, we could classify the protein *trans*-splicing reactions in foreign contexts with a simple kinetic model into three groups according to their kinetic parameters in the presence of various reducing agents.

Conclusion: The shorter C-intein of the newly engineered split intein could be a useful tool for biotechnological applications including protein modification, incorporation of chemical probes, and segmental isotopic labelling. Based on kinetic analysis of the protein splicing reactions, we propose a general strategy to improve ligation yields by protein *trans*-splicing, which could significantly enhance the applications of protein ligation by protein *trans*-splicing.

Citation: Aranko AS, Züger S, Buchinger E, Iwai H (2009) *In Vivo* and *In Vitro* Protein Ligation by Naturally Occurring and Engineered Split DnaE Inteins. PLoS ONE 4(4): e5185. doi:10.1371/journal.pone.0005185

Editor: Hilal Lashuel, Swiss Federal Institute of Technology Lausanne, Switzerland

Received: January 11, 2009; **Accepted:** March 5, 2009; **Published:** April 13, 2009

Copyright: © 2009 Aranko et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the grants from NSERC (298493), Sigrid Juselius Foundation, and the Academy of Finland (118385). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: hideo.iwai@helsinki.fi

^{1a} Current address: Biochemisches Institut der Universität Zürich, Zürich, Switzerland

^{1b} Current address: Department of Biotechnology, Chemistry and Environmental Engineering, Aalborg University, Aalborg, Denmark

Introduction

Protein splicing is a post-translational modification, in which an intervening protein splicing domain (intein) catalyzes ligation of the two flanking N- and C-terminal segments (N-extein and C-extein) by a peptide bond and concomitantly excises itself from the precursor protein [1–3]. Protein splicing can also take place in *trans* by ligating separate protein fragments containing each half of a naturally or artificially split intein (N-intein and C-intein) [4–6]. This protein *trans*-splicing (PTS) could also work in foreign contexts where the naturally occurring extein segments are replaced with other foreign protein sequences of interest. Therefore, protein *trans*-splicing can be used for ligation of polypeptide chains with a peptide bond for protein semi-synthesis, protein cyclization, segmental isotopic labelling, and site-specific protein modifications [7–12]. Protein *trans*-splicing has also been exploited to control protein functions in living organisms as a post-translational modification [13–15]. Thus, protein *trans*-splicing could be widely used in biotechnology and chemical biology [16].

Inteins usually consist of two domains, namely, a Hint domain and an endonuclease domain [3]. Since only the Hint domain is required for protein splicing, several inteins have been minimized

by removing the endonuclease domain for biotechnological applications [17–19]. The Hint domain could be reduced to as small as 135 residues, which is presumably the minimal functional length [19]. Naturally occurring split inteins contain 102–111 residues for N-intein (Int_N) and 35–36 residues for C-intein (Int_C) [20]. Short functional fragments of inteins have been of special interest because they could be easily prepared by chemical synthesis [12] and widen applications of protein *trans*-splicing for chemical modifications and protein semi-synthesis [21]. The shortest fragment identified so far is the N-terminal 11 residues of *Synechocystis sp.* PCC6803 (*Ssp*) DnaB intein [22]. Our interest was to identify functional split DnaE inteins with a shorter C-intein. Shorter C-inteins could be used as a ligation tag that can be easily synthesized or fused with other proteins for protein ligation.

In this study, a series of split DnaE inteins with new split sites have been constructed and tested for protein ligation both *in vivo* and *in vitro* to identify a functional split DnaE intein with a minimal C-terminal fragment. The robustness of the short C-intein has been tested by ligation of two domains that could not be ligated by wild-type DnaE intein. We also investigated the effect of extein sequences on protein ligation by protein *trans*-splicing. The effect of various reducing agents on *in vitro* protein ligation was tested with several target proteins.

of which expression was under the control of an inducible T7 promoter [8]. Previously, we found that the change of the N-terminal junction sequence of EY from *SspDnaE* to other sequences such as GS had little influence on the ligation yield [24]. Therefore, we used a linker of GS originated from the restriction site of *Bam*HI between GB1 and *SspDnaE-Int_N*. *SspDnaE-Int_{C_S}* were also fused to a chitin binding domain (CBD), of which expression was controlled by an arabinose promoter (Figure S1). We kept the sequence of CFNK from the wild-type junction sequence of *SspDnaE* and added GT for the cloning site of *Kpn*I as a linker between *SspDnaE-Int_{C_S}* and CBD [8]. GB1 and CBD were used here as model proteins because they are small soluble proteins. The N- and C-precursor proteins were genetically encoded into two separate plasmids that bear the compatible RSF3010 and ColE1 origins [8]. Seven plasmids for each half were constructed for testing *in vivo* and *in vitro* protein ligation (Table S1 and Figure S1).

In vivo protein *trans*-splicing by the new split *SspDnaE* inteins

Protein ligation by the new split inteins was tested *in vivo* using the dual vector system previously developed in our group [8]. This system allows us to conveniently check protein ligation because protein ligation could be initiated by the induction of the two precursor fragments with the two inducers, isopropyl- β -D-thiogalactoside (IPTG) and arabinose, and subsequently analyzed by SDS-PAGE [24]. Moreover, endogenous auxiliary factors such as chaperones might improve protein ligation in cells by promoting correct protein folding. The C-terminal part was always first induced for 0.5 hours ensuring an excess of the C-terminal precursor prior to the expression of the N-terminal precursor, and followed by the induction of the N-terminal precursor for another 3.5–5.5 hours. The pre-existing C-terminal precursor protein could be converted into the ligated product through protein *trans*-splicing after the association with the N-terminal part and protein splicing. The expression level of the N-terminal fragment was monitored by SDS-PAGE in order to avoid an enormous excess of the N-terminal part, which could underestimate the ligation yields. Immobilized Metal Affinity Chromatography (IMAC) was used to purify the N-terminal His-tagged precursor, the ligated product, and, if any, the cleaved N-terminal GB1 produced by the side reactions (Figure 1a). If *in vivo* protein ligation works with 100% efficiency and if there is no excess of the N-terminal precursor, only H₆-GB1-CBD will be purified by IMAC through the N-terminal His-tag. If the N- and C-terminal fragments associate with each other but no protein splicing is induced, both N- and C-terminal fragments (H₆-GB1-*SspDnaE-Int_N* and *SspDnaE-Int_C*-CBD) will be purified owing to the affinity between them. Furthermore, if the N- and C-inteins do not interact or if the C-terminal cleavage reaction is the dominant reaction after association of the N- and C-inteins, a single band of the N-terminal precursor is expected to be visible in the SDS gel. In some cases, during protein purification and sample preparation for SDS-PAGE, reactions such as splicing and cleavages could take place, which produced smaller bands of cleaved and spliced products. The ligated product was confirmed by mass-spectrometry (Figure S2). We could identify the ligated product H₆-GB1-CBD in the elution fractions from IMAC only for the combinations of *SspDnaE-Int_{N123}/SspDnaE-Int_{C36}* (wild-type), *SspDnaE-Int_{N130}/SspDnaE-Int_{C30}*, *SspDnaE-Int_{N137}/SspDnaE-Int_{C23}*, and *SspDnaE-Int_{N144}/SspDnaE-Int_{C16}* (Figure 2a). The ligation yields were estimated from the ratios between the intensities of the ligated product and one of the most abundant residual precursor fragments in the SDS gel, which were ca. 3%

for *SspDnaE-Int_{N144}/SspDnaE-Int_{C16}*, ca. 1% for *SspDnaE-Int_{N137}/SspDnaE-Int_{C23}*, and ca. 16% for *SspDnaE-Int_{N130}/SspDnaE-Int_{C30}*. These efficiencies might be underestimated if an excess of the N-terminal part was present during the expression due to the co-purification of the N-terminal precursor containing an N-terminal His-tag. The highest yield was estimated for the wild-type combination of *SspDnaE-Int_{N123}/SspDnaE-Int_{C36}* (67%). Albeit the amounts of the ligated products produced by the newly engineered inteins were very small, the protein ligation was still detectable by SDS-PAGE. The split site of *SspDnaE-Int_{N144}/SspDnaE-Int_{C16}* was the split site of the shortest C-intein retaining detectable splicing activity. However, the ligation efficiency was significantly lower than that of wild-type *SspDnaE* intein because of the low splicing activity and the side reactions. The pairs of *SspDnaE-Int_{N151}/SspDnaE-Int_{C9}* and *SspDnaE-Int_{N154}/SspDnaE-Int_{C6}* could not induce protein *trans*-splicing as only the N-terminal precursor was purified, indicating there was no significant interaction between them. On the other hand, the shortest C-intein construct of *SspDnaE-Int_{C3}* was purified together with the N-terminal *SspDnaE-Int_{N157}* indicating that there was sufficient interaction between them. However, we could not identify any ligated product although there was a band at 18.4 kDa in the SDS gel indicating a small amount of the N-cleavage reaction that produced Int_N.

Split *NpuDnaE* intein with the new split site

The low ligation efficiencies of the newly functional split sites of *SspDnaE* intein suggest little practical use of these new split inteins. However, we have recently discovered that DnaE intein from *Nostoc punctiforme* (*Npu*) has more robust protein *trans*-splicing activity than that of *SspDnaE* intein and is also more tolerant of amino acid replacements at the C-terminal splicing junction [24]. Our previous study indicated that the N-terminal part (*NpuDnaE-Int_N*) is responsible for the higher ligation efficiency [24]. Therefore, we were interested in introducing the new split site of *SspDnaE* intein into *NpuDnaE* intein to obtain sufficient protein *trans*-splicing activity for practical use. The new split site with the C-terminal 16 residues in *SspDnaE* is located between β -strands 10 and 11 (Figure 1b). We decided to shorten the C-intein by one more residue in *NpuDnaE* intein because based on the NMR structures of *NpuDnaE* intein (PDB entry, 2KEQ) the split site would be still in the loop between β -strands 10 and 11 [25,26]. Protein ligation *in vivo* by *NpuDnaE-Int_{N123}/NpuDnaE-Int_{C15}* is demonstrated in Figure 2b. The C-terminal part (*NpuDnaE-Int_{C15}*-GB1) was induced first by L-arabinose (lane 2, Figure 2b). After the consecutive induction of the N-terminal part (H₆-GB1-*NpuDnaE-Int_{N123}*), a large amount of the ligated product (H₆-GB1-GB1) was accumulated (lane 3 and 4, Figure 2b). The fraction purified by IMAC contained almost no precursor proteins and the ligation was confirmed by mass spectrometry (lane 5, Figure 2b and Figure S3). We estimated the ligation efficiency to be ca. 96%, which is significantly better than any of the tested combinations of the newly split *SspDnaE* inteins. We also tested protein ligation by the combination of *NpuDnaE-Int_{N123}/SspDnaE-Int_{C16}*, which resulted in similar ligation efficiency (data not shown). This result emphasizes the dominant contribution of the N-intein to the ligation efficiency and suggests that the sequence variation between *NpuDnaE-Int_{C15}* and *SspDnaE-Int_{C16}* (the sequence identity is 66%) has little influence on protein *trans*-splicing efficiency.

Protein ligation of SH3 domains by the naturally split *NpuDnaE* intein

The robustness of naturally split *NpuDnaE* intein encouraged us to use *NpuDnaE* intein as a general tool for protein ligation and to apply it to biologically relevant proteins [24]. The Src




Figure 2. *In vivo* protein ligations by the newly engineered split *SspDnaE* and *NpuDnaE* inteins. (a) SDS-PAGE analysis of *in vivo* protein ligations by the newly engineered split *SspDnaE* inteins after purification with Ni-NTA. The combinations of *SspDnaE*-Int_N and *SspDnaE*-Int_C are indicated on the top of the lanes. (b) *In vivo* protein ligation by *NpuDnaE* intein with the newly engineered split site (*NpuDnaE*-Int_{N123/C15}). Lane 1, before induction; lane 2, 1.5 hours after induction only with arabinose; lane 3, 1.5 hours after additional induction with IPTG; lane 4, 3 hours after induction with IPTG and arabinose; lane 5, elution from Ni-NTA column. doi:10.1371/journal.pone.0005185.g002


homology 3 (SH3) domain is one of the most abundant domains in multi-domain proteins. Therefore, we were interested in protein ligation of the two SH3 domains from c-Crk-II adaptor protein [27]. Despite the robustness of *NpuDnaE* intein, protein ligation of the two SH3 domains by wild-type *NpuDnaE* intein was not possible, because the side reactions were dominating the *trans*-splicing and producing mainly cleaved products (Figure 3a and 3c). When the N-terminal SH3 (nSH3) was replaced with the model protein GB1, both *in vivo* and *in vitro* ligation of the two proteins by protein *trans*-splicing was still not possible with high yields (Figure 3b and 3d, Figure S4). On the other hand, the ligation of the two proteins *in vitro* as well as *in vivo* was

significantly improved after replacing the C-terminal SH3 (cSH3) with GB1 (Figure 4a, Table 1). These observations indicate that protein *trans*-splicing can be significantly influenced not only by the sequences near the splicing junctions but also by the exteins, which brings additional complexity to protein *trans*-splicing. Furthermore, the replacement of the C-terminal precursor protein suggests that the C-terminal fragment containing cSH3 negatively affects the protein ligation.

The effect of reducing agent on *trans*-splicing

In theory, protein *trans*-splicing does not require any thiol agents for the reaction [3]. However, both N- and C-inteins of *NpuDnaE*

in vivo



in vitro




Figure 3. Protein ligation *in vivo* and *in vitro* by the naturally occurring split *NpuDnaE* intein. (a) Protein ligation of nSH3 and cSH3 *in vivo* by naturally occurring split *NpuDnaE* intein. Lane 0, before induction; lane 1, 1 hour after the induction with IPTG and arabinose; lane 2, 2 hours; lane 3, 4 hours; lane 4, 6 hours. (b) Protein ligation of GB1 and cSH3 *in vivo* by the wild-type *NpuDnaE* intein. Lane 0, before induction; lane 1, 2 hours after the induction with IPTG and arabinose; lane 2, 4 hours; lane 3, 6 hours. *In vitro* protein ligation (c) of nSH3 and cSH3 (d) of GB1 and cSH3 in the presence of 50 mM DTT. Lane 0, 0 min after the mixing; lane 1, 10 min; lane 2, 3 hours; lane 3, 24 hours for (c). Lane 0, 0 min after the mixing; lane 1, 3 min; lane 2, 3 hours; lane 3, 24 hours for (d). Asterisks indicating the bands below 14.4 kDa in (c) and (d) are impurities from the purification of H_6 -NpulInt_{C36}-cSH3.

doi:10.1371/journal.pone.0005185.g003

intein contain unpaired cysteine residues that could form intermolecular disulfide bonds and they may prevent the appropriate association of the two fragments. Therefore, it is desirable to keep the reaction under reducing conditions with a sulfhydryl reductant. In a previous study on *SspDnaE* intein, it has been reported that the presence of 50 mM dithiothreitol (DTT) would almost totally block protein *trans*-splicing and instead shunt the reaction to *trans*-cleavage [28]. As a sulfhydryl reductant, we have tested two thiol agents (DTT and 2-mercaptoethane sulfonic acid, MESNA) and a trialkylphosphine (tris(2-carboxyethyl)phosphine, TCEP) that is unreactive with thiol groups such as cysteine (Figure 4c). In contrast to the previous report, we found that the effect of various reducing agents on protein ligation was negligible for the ligation between nSH3 and GB1 (Figure 4c) as well as for the ligation of the two SH3 domains (data not shown). In the case of nSH3 and cSH3, the reaction was always dominated by *trans*-

cleavage rather than *trans*-splicing (Table 1, Figure 3). It was not possible to improve the ligation of those SH3 domains by replacing the reducing agent. For the ligation of nSH3 and GB1, *trans*-splicing was always observed regardless of the reducing agents used (Table 1, Figure 4c). To understand these puzzling effects, we analyzed the kinetics of the protein ligation. It is well accepted that protein-splicing reaction involves the four concerted steps: (1) N-S acyl shift, (2) *trans*-thioesterification, (3) Asn cyclization, and (4) S-N acyl shift, and possibly undesired side reactions of N- and C-cleavage (Figure 1a) [29]. The detailed kinetics of the individual steps has been previously characterized for *SspDnaE* intein [28]. We decided to approximate the reactions with a simple kinetic model as depicted in (I), in which the entire reaction was divided into the two parallel reactions: *trans*-splicing and cleavage reactions because the two reactions are both irreversible processes. In this model, we also assume that the formation of the precursor




Figure 4. In vitro protein ligation of nSH3 and GB1 by the naturally occurring split *NpuDnaE* intein. (a) Time course of the protein ligation of nSH3 and GB1 by naturally occurring split *NpuDnaE* intein in the presence of 50 mM DTT. Lane 1, 0 min after the mixing; lane 2, 3 min; lane 3, 10 min; lane 4, 30 min; lane 5, 1 hour; lane 6, 3 hours; lane 7, 22 hours. (b) Kinetic analysis of the protein ligation from the SDS-PAGE. (c) SDS-PAGE analysis of the ligation reaction after overnight incubation in the presence of different reducing agents. doi:10.1371/journal.pone.0005185.g004

complex is fast relative to the subsequent reaction steps and the dissociation constant is much smaller than the protein concentration used in the experiments [28].



A = precursor complex, B = ligated product, C = cleaved product, k_{trans} = 1st order kinetic constant for *trans*-splicing, and k_{unprod} = apparent 1st order kinetic constant for all unproductive side reactions including the N- and C-terminal cleavage reactions. Time courses of the products can be formulated by the following rate equations.

Table 1. The final yields of the protein ligation by protein *trans*-splicing.

Intein	N-extein	C-extein	Yield (%) with 50 mM DTT	Yield (%) with 0.5 mM TCEP
<i>NpuDnaE</i> -Int _{N102/C36} (wild-type)	nSH3	cSH3	n.d.	n.d.
	GB1	cSH3	n.d.	n.d.
	nSH3	GB1	77 ± 10	61 ± 8
<i>NpuDnaE</i> -Int _{N123/C15}	nSH3	cSH3	27 ± 10	50 ± 7
	Smt3	GB1	9 ± 3	65 ± 7

n.d., not detectable.

doi:10.1371/journal.pone.0005185.t001

$$\begin{aligned} \frac{d[A]}{dt} &= -(k_{unprod} + k_{trans})[A], \\ \frac{d[B]}{dt} &= k_{trans}[A], \quad \frac{d[C]}{dt} = k_{unprod}[A] \end{aligned} \quad (\text{II})$$

These equations can be easily solved [30]. The yield of the ligation at an infinite time can be derived from the two kinetic constants for *trans*-splicing and cleavage according to Eq. (III).

$$E(\%) = 100 \times \frac{k_{trans}}{k_{trans} + k_{unprod}} \quad (\text{III})$$

With this model, we should be able to estimate ligation yields from the rate constants of *trans*-splicing and side reactions, and *vice versa*. For the ligation between nSH3 and GB1, $2.3 \pm 0.2 \times 10^{-4}$ (s^{-1}) was estimated for k_{trans} in the presence of 50 mM DTT (Figure 4b). According to Eq. (III) using the obtained kinetic constants and the reported DTT induced cleavage rate constant for *Ssp*DnaE intein ($1.0 \pm 0.5 \times 10^{-3}$ (s^{-1})) [28], the ligation yield for nSH3 and GB1 is expected to be 12–33%. However, the obtained final yield of close to 80% might suggest that the rate constant of DTT induced cleavage is about 1×10^{-4} with this

system (Table 1). *Trans*-splicing was not detectable for nSH3 and cSH3, but the side reactions were dominant with the kinetic constant $k_{unprod} = 5.4 \pm 0.4 \times 10^{-4}$ (s^{-1}) in the presence of 50 mM DTT (data not shown). Although the replacement of DTT with TCEP as a reducing agent slowed the unproductive cleavage reactions, *trans*-splicing was not detectable. This suggests that *trans*-splicing reaction occurs at a significantly slower rate than the cleavage reaction. This model assumes that the association rates are fast and that the dissociation rates are similarly low for different exteins compared with the experimental concentration. Therefore, when the estimation of the yield is largely discrepant with the kinetic constants, the limiting factor is likely to be imposed by the association rate. Thus, this simple model and the kinetic analysis might provide a useful tool to predict final yields as well as to identify the rate-limiting step in protein *trans*-splicing reaction.

Protein ligation by the newly engineered split *Npu*DnaE

From the aforementioned results with the SH3 domains, we assumed that the C-intein fused with cSH3 is the limiting factor for the protein ligation of two SH3 domains, inducing fast cleavage reactions. We believe that cSH3 probably interferes with association of N- and C-inteins of wild-type *Npu*DnaE intein and that the shorter C-intein might not interfere the ligation of the two SH3 domains. Therefore, we decided to replace the intein with the newly engineered *Npu*DnaE intein (*Npu*DnaE-Int_{N123}/*Npu*DnaE-Int_{C15})




Figure 5. Protein ligation of two SH3 domains by the newly engineered split *Npu*DnaE intein. (a) SDS-PAGE analysis of the time course from the protein ligation reaction of nSH3 and cSH3 in the presence of 0.5 mM TCEP. Lane 1, 0 min after the mixing; lane 2, 3 min; lane 3, 10 min; lane 4, 30 min; lane 5, 1 hour; lane 6, 3 hours; lane 7, 22 hours. (b) Kinetic analysis of the protein ligation from the SDS-PAGE. doi:10.1371/journal.pone.0005185.g005




Figure 6. Protein ligation of Smt3 and GB1 by the newly engineered split *NpuDnaE* intein. Time courses and kinetic analysis of protein ligation in the presence of (a) 0.5 mM TCEP or (b) 50 mM DTT. SDS-PAGE: lane 1, 0 min after the mixing; lane 2, 3 min; lane 3, 10 min; lane 4, 30 min; lane 5, 1 hour; lane 6, 3 hours; lane 7, 24 hours.
doi:10.1371/journal.pone.0005185.g006

for the ligation. As demonstrated in Figure 5, the new split *NpuDnaE* intein could indeed ligate nSH3 and cSH3 that were not possible to be ligated by the naturally occurring split *NpuDnaE* intein. It demonstrates the effectiveness of the shorter C-intein in the case of difficult ligations such as the one between the two SH3 domains. The kinetic constants for *trans*-splicing were estimated to be $4.8 \pm 0.3 \times 10^{-5} \text{ (s}^{-1}\text{)}$ in the presence of 0.5 mM TCEP (Figure 5b). Thus, the engineered split *NpuDnaE* intein can significantly improve the protein ligation by accelerating the *trans*-splicing reaction.

Protein ligation of Smt3 and GB1

Because of the strong influence of the extein sequences on protein *trans*-splicing, we wanted to test another small protein with a similar size, the yeast ubiquitin-like protein Smt3, for protein ligation [31]. Protein ligation of His-tagged Smt3 and GB1 by *NpuDnaE*- Int_{N123} was tested in the presence of either 50 mM DTT or 0.5 mM TCEP. The protein ligation of Smt3 and GB1 responded differently to the two different reducing agents. When 0.5 mM TCEP was used, the yield was more than 60–70%. On the contrary, only about 10% of the protein ligation was achieved in the presence of 50 mM DTT, where the cleavage reaction dominated. In this case the kinetic constant for *trans*-splicing in presence of 0.5 mM TCEP was estimated to be $8.3 \pm 0.7 \times 10^{-5} \text{ (s}^{-1}\text{)}$. DTT induced the dominant cleavage reaction with a kinetic constant of $9.2 \pm 1.2 \times 10^{-4} \text{ (s}^{-1}\text{)}$ (Figure 6). The protein ligation yield in the presence of 50 mM DTT is expected to be around 10% as it can be derived from Eq. (III) with an assumption that *trans*-splicing rates are similar for both DTT and TCEP. This is in good agreement with the yield obtained

experimentally, suggesting that the simple model is appropriate for roughly estimating the yield without any intricate methods.

Discussion

In this article, we demonstrated that C-intein from *SypDnaE* and *NpuDnaE* inteins could be shortened to C-terminal 16 or 15 residues without abolishing protein *trans*-splicing activity. The newly engineered split *NpuDnaE* intein bearing the C-terminal 15 residues as C-intein retained robust protein *trans*-splicing activity. The use of the shorter C-intein was even more effective for the ligation of the two SH3 domains that could not be ligated by the wild-type split *DnaE* inteins. The shorter length of C-intein of the engineered split *NpuDnaE* intein could be attractive for chemical synthesis and suitable for incorporation of chemically modified peptides by protein *trans*-splicing [32]. Moreover, the kinetic analysis of the ligation reaction could be important because the kinetic parameters are the key factor determining the ligation yields. The analysis using a simple parallel model to approximate the reaction could be a convenient tool to investigate the rate-limiting steps in the reaction and to estimate the ligation yields based on the kinetic parameters. Protein *trans*-splicing reaction in foreign contexts can be categorized into three groups. In the first group only side reactions of cleavages can be observed. Various reducing agents such as TCEP or DTT have little effect on improving protein ligation in this group. In this case, the cleavage reaction has a typical kinetic constant of $>1 \times 10^{-4} \text{ (s}^{-1}\text{)}$ and the *trans*-splicing rate is much slower than the cleavage rate. In the

second group, regardless of the used reducing agents, protein ligation by protein *trans*-splicing can be observed. Here, the *trans*-splicing reaction is faster ($>1 \times 10^{-4}$ (s⁻¹)) than the unproductive cleavage reactions induced by various reducing agents. In the third group, *trans*-splicing reaction is slower than the side reactions induced by DTT, but faster than the side reactions in the presence of TCEP. Therefore, the reducing agent could greatly influence the final yield. This is presumably because the thiol group of DTT is a nucleophile competing with the thiol of the first cysteine of C-intein and induces dominant cleavage reactions. However, the side reactions in the presence of TCEP are usually slower because it has no thiol group that functions as nucleophile competing with *trans*-splicing reaction.

In summary, we could create new functional split inteins with shorter C-inteins, which retained *trans*-splicing activity. Protein *trans*-splicing was found to be dependent on the protein sequences of the exteins even if the sequence around the splicing junctions were identical. How the exteins influence protein *trans*-splicing remains unclear. However, monitoring the kinetics of the protein *trans*-splicing reaction could be a useful tool to identify the rate-limiting steps in protein ligation reaction. To achieve a higher yield of protein ligation by protein *trans*-splicing, it is of importance to keep the competing side reactions slower than the *trans*-splicing reaction by replacing the reducing agent with non-thiol reducing agents such as TCEP or by accelerating the *trans*-splicing reaction using a more efficient split intein. The ligation between self-contained domains by protein *trans*-splicing was investigated in this article. However, the model describing the relation between *trans*-splicing and side reactions should be generally applicable even for the ligation within a single domain although such ligation may require refolding of the precursors which could be a more dominant factor affecting the yield. Further understanding of the factors influencing protein *trans*-splicing reaction rates such as folding processes of split inteins and engineering of split inteins could make protein *trans*-splicing a more versatile tool for protein modification, protein semi-synthesis, and segmental isotopic labelling.

Materials and Methods

Construction of plasmids

The N-terminal fragments of *Syp*DnaE intein (*Syp*DnaE-Int_N) of various lengths were previously constructed [24]. The coding sequences of *Syp*DnaE-Int_Ns were subcloned into pJJDuet30 between *Bam*HI and *Hind*III sites [8], resulting in the sequences coding for H₆-GB1-*Syp*DnaE-Int_Ns (Figure S1). *Syp*DnaE-Int_Cs of various lengths were constructed from the plasmid pSZRS1 containing the gene of the full-length *Syp*DnaE-Int_C and the chitin binding domain (CBD) using synthetic oligonucleotides (Table S1) and cloned into pBAD vector (Figure S1).

The plasmid for H₆-GB1-*Npu*DnaE-Int_{N123} was constructed by replacing the codon of residue 124 of the full-length *Npu*DnaE intein with a stop codon in the plasmid of pSKDuet16, resulting in pHYDuet36 [26]. The plasmid pSKDuet16 contains an additional two mutations of HM to LG at the front of GB1 due to the replacement of *Nde*I site by *Avr*II site, compared with the plasmids derived from pJJDuet30 [8]. The gene of *Npu*DnaE-Int_{C15}-GB1 was amplified from pSKDuet16 and cloned into a pBAD vector (pHYBAD44) [24]. *Npu*DnaE-Int_{N123} was subcloned from pHYDuet36 into pHYRSF53LA using *Bam*HI and *Hind*III sites, which resulted in pHYRSF53-36 coding for H₆-Smt3-*Npu*DnaE-Int_{N123} [26].

The gene of the N-terminal SH3 domain was amplified from pAT044 [33] with the two oligonucleotides (#HK009 and #SK202) and cloned into pHYRSF1-12 using *Nde*I and *Ahd*I

sites, which resulted in pTMRSF07 (Table S1). The plasmid pHYRSF1-12 was previously constructed by transferring the gene of GB1 and the N-terminal *Npu*DnaE from pSKDuet1 into pRSF-1b using *Nco*I and *Hind*III sites. The plasmid of pHYRSF1-12 contains additional mutations of GS to TK to introduce *Ahd*I site at the front of *Npu*DnaE intein. The gene of the C-terminal SH3 domain was amplified from pAT044 with the two oligonucleotides (#SK199 and #SK200) and cloned into pSKBAD2 using *Kpn*I and *Hind*III sites (pHYBAD2-03) (Table S1). The plasmid pSARSF03, which codes for H₆-*Npu*DnaE-Int_{C36}-cSH3, was constructed by subcloning the genes of Int_{C36} and cSH3 into pHYRSF1-2 by *Nde*I and *Hind*III sites. The plasmids (pMMRSF17 for nSH3 and pMMRSF1-16 for cSH3) coding for the SH3 domains fused to the newly designed split *Npu*DnaE intein were previously described [34].

Expression and purification of new split inteins

His-tagged DnaE-Int_Ns fused with GB1, Smt3, or SH3 domains were purified using His-Trap columns (GE Healthcare) under native condition. The DnaE-Int_Cs without a His-tag fused with GB1 were purified with IgG sepharose (GE Healthcare) according to the manufacturer's protocol. The eluted fractions of DnaE-Int_Cs were dialyzed against 10 mM Tris, 500 mM NaCl, 1 mM EDTA, pH 7.0 prior to protein ligation.

In vivo protein ligation

Each pair of the two plasmids encoding N- or C-terminal precursor proteins was transformed into *E. coli* ER2566 (New England Biolabs) for protein expression. The cells bearing these two plasmids were grown in 25 ml LB medium supplemented with 100 μg/ml ampicillin and 25 μg/ml kanamycin. The plasmid containing DnaE-Int_C was first induced for 0.5 hours at a final concentration of 0.04% arabinose when the cell density reached OD₆₀₀ = 0.5–0.8, followed by an additional induction of the N-terminal part with addition of a final concentration of 1 mM isopropyl-β-D-thiogalactoside (IPTG). Expression was carried out for another 4–5.5 hours. The cells were spun down at 4,500 ×g for 10 min and stored at -20°C for further purification. The harvested cells were lysed by ultrasonication in lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, pH 8.0). The cell debris was removed from the protein solution by centrifugation for 15 min at 18,000 ×g. The entire amount of the supernatant was loaded on a Ni-NTA spin column (Qiagen) equilibrated with lysis buffer and centrifuged for 2 min at 700 ×g. The column was washed twice with 600 μl washing buffer (50 mM sodium phosphate, 300 mM NaCl, 30 mM imidazole, pH 8.0). The bound protein was eluted from the spin column by washing twice with 200 μl elution buffer (50 mM sodium phosphate, 300 mM NaCl, 250 mM imidazole, pH 8.0).

In vitro protein ligation

Equal amounts of the two precursor fragments (final concentrations of 15 μM) were mixed in the presence of final concentrations of 1 mM EDTA and either 50 mM DTT (dithiothreitol), 20 mM MESNA (2-mercaptoethane sulfonic acid), or 0.5 mM TCEP (tris(2-carboxyethyl)phosphine). The reactions were incubated at 25°C with shaking. The samples for SDS-PAGE analysis were typically taken at 0 min, 3 min, 10 min, 30 min, 1 hour, 3 hours, and 24 hours after mixing. The reactions were stopped by adding an equal amount of 1 × SDS sample buffer containing 2-mercaptoethanol and stored at -20°C for over night. The samples were loaded on 18% SDS polyacrylamide gels after the incubation at 95°C for 5 min. The ligation yields were estimated from the intensities of the bands in the SDS-gels colored

with Coomassie brilliant blue (PhastGel Blue R, GE Healthcare) by quantifying the scanned gels with ImageJ (NIH). The amounts of proteins were calculated with the assumption that the staining dye binds to the proteins equally. The errors were estimated by at least three independent reactions.

Supporting Information

Table S1 List of the used oligonucleotides

Found at: doi:10.1371/journal.pone.0005185.s001 (0.06 MB DOC)

Figure S1 The summary of the constructs for the newly engineered split SspDnaE inteins

Found at: doi:10.1371/journal.pone.0005185.s002 (0.01 MB PDF)

Figure S2 The mass spectrum of the elution fraction from *In vivo* ligation of GB1 and CBD by SspDnaE intein.

Found at: doi:10.1371/journal.pone.0005185.s003 (0.17 MB PDF)

References

- Hirata R, Ohsumi Y, Nakano A, Kawasaki H, Suzuki K, et al. (1990) Molecular structure of a gene, VMA1, encoding the catalytic subunit of H(+)-translocating adenosine triphosphatase from vacuolar membranes of *Saccharomyces cerevisiae*. *J Biol Chem* 265: 6726–6733.
- Kane PM, Yamashiro CT, Wolczyk DF, Neff N, Goebel M, et al. (1990) Protein splicing converts the yeast TFP1 gene product to the 69-kD subunit of the vacuolar H(+)-adenosine triphosphatase. *Science* 250: 651–657.
- Paulus H (2000) Protein splicing and related forms of protein autoprocessing. *Ann Rev Biochem* 69: 447–496.
- Mills KV, Lew BM, Jiang S, Paulus H (1998) Protein splicing in trans by purified N- and C-terminal fragments of the *Mycobacterium tuberculosis* RecA intein. *Proc Natl Acad Sci U.S.A.* 95: 3543–3548.
- Southworth MW, Adam E, Panne D, Byer R, Kautz R, et al. (1998) Control of protein splicing by intein fragment reassembly. *EMBO J* 17: 918–926.
- Wu H, Hu Z, Liu XQ (1998) Protein trans-splicing by a split intein encoded in a split DnaE gene of *Synechocystis* sp. PCC6803. *Proc Natl Acad Sci U.S.A.* 95: 9226–9231.
- Yamazaki T, Otomo T, Oda N, Kyogoku Y, Uegaki K, et al. (1998) Segmental isotope labeling for protein NMR using peptide splicing. *J Am Chem Soc* 120: 5591–5592.
- Züger S, Iwai H (2005) InteIn-based biosynthetic incorporation of unlabeled protein tags into isotopically labeled proteins for NMR studies. *Nat Biotechnol* 23: 736–740.
- Iwai H, Lingel A, Plückthun A (2001) Cyclic green fluorescent protein produced *in vivo* using an artificially split PI-PflII intein from *Pyrococcus furiosus*. *J Biol Chem* 276: 16548–16554.
- Williams NK, Prossellkov P, Liepinsh E, Line I, Sharipo A, et al. (2002) *In vivo* protein cyclization promoted by a circularly permuted *Synechocystis* sp. PCC6803 DnaB mini-intein. *J Biol Chem* 277: 7790–7798.
- Evans TC, Martin D, Kolly R, Panne D, Sun L, et al. (2000) Protein trans-splicing and cyclization by a naturally split intein from the *dnaE* gene of *Synechocystis* species PCC6803. *J Biol Chem* 275: 9091–9094.
- Ludwig C, Pfeiff M, Linne U, Mootz HD (2006) Ligation of a synthetic peptide to the N terminus of a recombinant protein using semisynthetic protein trans-splicing. *Angew Chem Int Ed* 45: 5218–5221.
- Mootz HD, Blum ES, Tyszkiewicz AB, Muir TW (2003) Conditional protein splicing: a new tool to control protein structure and function *in vitro* and *in vivo*. *J Am Chem Soc* 125: 10561–10569.
- Schwartz EC, Saez L, Young MW, Muir TW (2007) Post-translational enzyme activation in an animal via optimized conditional protein splicing. *Nat Chem Biol* 3: 50–54.
- Buskirk AR, Ong YC, Gartner ZJ, Liu DR (2004) Directed evolution of ligand dependence: small-molecule-activated protein splicing. *Proc Natl Acad Sci U.S.A.* 101: 10505–10510.
- Xu MQ, Evans TC, Jr (2004) Recent advances in protein splicing: manipulating proteins *in vitro* and *in vivo*. *Curr Opin Biotechnol* 16: 440–446.
- Derbyshire V, Wood DW, Wu W, Dansereau JT, Dalgaard JZ, et al. (1997) Genetic definition of a protein-splicing domain: functional mini-inteins support structure predictions and a model for intein evolution. *Proc Natl Acad Sci U.S.A.* 94: 11466–11471.
- Wu H, Xu MQ, Liu XQ (1998) Protein trans-splicing and functional mini-inteins of a cyanobacterial dnaB intein. *Biochim Biophys Acta* 1387: 422–432.
- Hiraga K, Derbyshire V, Dansereau JT, Van Roy P, Belfort M (2005) Minimization and stabilization of the *Mycobacterium tuberculosis* recA intein. *J Mol Biol* 354: 916–926.
- Dassa B, Amitai G, Caspi J, Schueler-Furman O, Pietrovski S (2007) Trans protein splicing of cyanobacterial split inteins in endogenous and exogenous combinations. *Biochemistry* 46: 322–330.
- Kurpiers T, Mootz HD (2007) Regioselective cysteine bioconjugation by appending a labeled cystein tag to a protein by using protein splicing in trans. *Angew Chem Int Ed Engl* 46: 5234–5237.
- Sun W, Yang J, Liu XQ (2004) Synthetic two-piece and three-piece split inteins for protein trans-splicing. *J Biol Chem* 279: 35281–35286.
- Otomo T, Teruya K, Uegaki K, Yamazaki T, Kyogoku Y (1999) Improved segmental isotope labeling of proteins and application to a larger protein. *J Biomol NMR* 14: 105–114.
- Iwai H, Züger S, Jin J, Tam PH (2006) Highly efficient protein trans-splicing by a naturally split DnaE intein from *Nostoc punctiforme*. *FEBS Lett* 580: 1853–1858.
- Oeemig JS, Aranko AS, Djupsjöbacka J, Heinämäki K, Iwai H (2009) Solution structure of DnaE intein from *Nostoc punctiforme*: Structural basis for the design of a new split intein suitable for site-specific chemical modification. 10.1016/j.febslet.2009.03.058.
- Heinämäki K, Oeemig JS, Pääkkonen K, Djupsjöbacka J, Iwai H (2008) NMR resonance assignment of DnaE intein from *Nostoc punctiforme*. *Biomol NMR assign*; in press. DOI: 10.1007/s12104-008-9137-1.
- Reichman CT, Mayer BJ, Khawer S, Hanafusa H (1992) The product of the cellular crk gene consists primarily of SH2 and SH3 regions. *Cell Growth Differ* 3: 451–460.
- Martin DD, Xu MQ, Evans TC, Jr (2001) Characterization of a naturally occurring trans-splicing intein from *Synechocystis* sp. PCC6803. *Biochemistry* 40: 1393–1402.
- Perler FB, Xu MQ, Paulus H (1997) Protein splicing and autoproteolysis mechanisms. *Curr Opin Chem Biol* 1: 292–299.
- Fersht A (1999) Structure and mechanism in protein science, 2nd Ed. New York: W. H. Freeman and Company.
- Mossesova E, Lima CD (2000) Ulp1-SUMO structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. *Mol Cell* 5: 865–876.
- Iwai H, Aranko AS, Djupsjöbacka J (2008) Protein ligation using protein trans-splicing. *J Pept Sci* 14: Suppl. 183.
- Forrer P, Jaussi R (1998) High-level expression of soluble heterologous proteins in the cytoplasm of *Escherichia coli* by fusion to the bacteriophage lambda head protein D. *Gene* 224: 45–52.
- Muona M, Aranko AS, Iwai H (2008) Segmental isotopic labelling of a multi-domain protein by protein ligation using protein trans-splicing. *ChemBioChem* 9: 2958–2961.
- Sun P, Ye S, Ferrandon S, Evans TC, Xu MQ, et al. (2005) Crystal structures of an intein from the split *dnaE* gene of *Synechocystis* sp PCC6803 reveal the catalytic model without the penultimate histidine and the mechanism of zinc ion inhibition of protein splicing. *J Mol Biol* 353: 1093–1105.
- Ding Y, Xu MQ, Ghosh I, Chen X, Ferrandon S, et al. (2003) Crystal structure of a mini-intein reveals a conserved catalytic module involved in side chain cyclization of asparagine during protein splicing. *J Biol Chem* 278: 39133–39142.